Bristol-Myers Squibb Company (FRA:BRM)
Germany · Delayed Price · Currency is EUR | Market Cap | 80.94B |
| Revenue (ttm) | 40.62B |
| Net Income (ttm) | 4.30B |
| Shares Out | n/a |
| EPS (ttm) | 2.12 |
| PE Ratio | 18.83 |
| Forward PE | 7.25 |
| Dividend | 2.24 (5.66%) |
| Ex-Dividend Date | Jul 3, 2025 |
| Volume | 3,241 |
| Average Volume | 1,726 |
| Open | 39.70 |
| Previous Close | 39.50 |
| Day's Range | 39.70 - 40.38 |
| 52-Week Range | 37.66 - 58.79 |
| Beta | n/a |
| RSI | 49.81 |
| Earnings Date | Oct 30, 2025 |
About FRA:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
Bristol-Myers Squibb: Buy Before The Market Realizes Its Folly
Insider Decision: David V Elkins Offloads $2.65M Worth Of Bristol-Myers Squibb Stock
Making a noteworthy insider sell on September 3, David V Elkins , EVP at Bristol-Myers Squibb (NYSE: BMY), is reported in the latest SEC filing. What Happened: A Form 4 filing from the U.S. Securitie...
Alexandria Real Estate Equities, Inc. Named One of the World's Most Trustworthy Companies by Newsweek for the Second Consecutive Year
PASADENA, Calif. , Sept. 4, 2025 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborativ...
Bristol-Myers Squibb: Not As Cheap As It Might Seem
Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025
Findings from COLLIGO-HCM reinforce Camzyos' efficacy and safety profile in reducing left ventricular outflow tract (LVOT) obstruction and improving symptom burden in a racially diverse, global patien...
Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025. The company will take pa...
Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of new clinical and real-world data from its cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking pla...
Final Trades: ServiceNow, Bristol Myers and Live Nation
The Investment Committee give you their top stocks to watch for the second half.
Agilent, Bristol Myers win FDA nod for cancer diagnostic test
How Do Investors Really Feel About Bristol-Myers Squibb?
Bristol-Myers Squibb's (NYSE: BMY) short percent of float has fallen 19.58% since its last report. The company recently reported that it has 30.92 million shares sold short , which is 1.52% of all re...
Price Over Earnings Overview: Bristol-Myers Squibb
Looking into the current session, Bristol-Myers Squibb Inc. (NYSE: BMY) shares are trading at $48.48, after a 0.08% increase. Moreover, over the past month, the stock went up by 0.96% , but in the pa...
RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program
Three major pharmaceutical companies — Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Co (NYSE: LLY), and UCB SA (OTC: UCBJY) (OTC: UCBJF) — are suing U.S. Secretary of Health and Human Services (HHS) R...
Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity
Bristol Myers gets priority review for Breyanzi's label expansion
Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) for Breyanzi (lisocabtagene maraleu...
Procurement leaders talk about how AI changing the way they plan, report, and solve problems
Industry experts from Amazon Business, Bristol Myers Squibb, and SMBC Americas discuss AI-driven procurement strategies at BI's virtual event.
Bristol-Myers Squibb: Buy The Weakness
Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks. Read why BMY stock is a buy.
Bristol-Myers Squibb: Declines Have Gone Too Far
Bristol-Myers Squibb's sales are stabilizing, with Q2 net sales up 1% YoY and growth portfolio drugs like Camzyos and Breyanzi showing strong momentum.
